Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 25Neoplasms 3Neoplasm Metastasis 3Stomach Neoplasms 1Sarcoma 1Osteitis Deformans 1Neoplastic Cells, Circulating 1Invasive Breast Cancer 1Head and Neck Neoplasms 1HER2-positive Advanced Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER2 Positive Metastatic Breast Cancer 1Esophageal Neoplasms 1Carcinoma 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

pyrotinib 2Capecitabine 2Lapatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × HER2 Positive Metastatic Breast Cancer × Lapatinib × Clear all
NCT03080805 2020-06-18

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
240 enrolled
Breast

HER2 Positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡